Clinical Trial Update: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

The Phase 1 study evaluating IGM-2644 in adults with relapsed and/or refractory multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IGM-2644

Snippet

Sponsor: IGM Biosciences, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED